Education only · provider review required
Cagrilintide · Amylin analogue in trials
A long-acting amylin analogue studied alone and combined with semaglutide (CagriSema).
Medically reviewed by Bernard Garcia, MD
What it is
Cagrilintide is an investigational long-acting analogue of amylin, a hormone released with insulin that affects satiety and gastric emptying. It is studied on its own and, more prominently, in a fixed combination with semaglutide known as CagriSema, which is in phase 3 trials.
How it works
Amylin analogues act on appetite centres through a different receptor from GLP-1, which is the rationale for combining the two. Phase 2 and 3 data report average weight reduction over 68 weeks; approval decisions are pending.
Research status
| Research area | Status |
|---|---|
| Weight management (with semaglutide) | Phase 3 trials · not approved |
| Weight management (alone) | Phase 2 · not approved |
| Long-term safety | Not established |
| Regulatory status (US FDA) | Investigational · no approval |
Status reflects published research context only and is not a statement of safety, efficacy, or suitability for any person.
Is it legal?
Cagrilintide is investigational and not approved in any country. This is a general note, not legal advice.
Frequently asked questions
Is cagrilintide available?
No. It is in clinical trials only.
How does it differ from GLP-1 medicines?
It mimics amylin, a different hormone, and is studied mainly as an add-on to semaglutide.
Will this page change?
Yes — it is re-reviewed when trial results or regulatory decisions are published.
Next step
Next step: a 3-minute confidential intake, reviewed by a licensed provider. No treatment is promised or implied.
Free · about 10 minutes · reviewed by a licensed physician
General education · Not medical advice · Provider approval required